Data presented concludes that miR-31-3p expression is predictive of anti-EGFR therapy effect on objective response, depth of response, and early tumor shrinkage in patients with metastatic colorectal cancer enrolled in prospective, randomized FIRE-3 Trial.

Click here to view press release